Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 9, 2010, Pages 914-924

  Sandoval, José C ^a   Nakagawa Toyama, Yumiko ^b   Masuda, Daisaku ^a   Tochino, Yoshihiro ^a   Nakaoka, Hajime ^a   Kawase, Ryota ^a   Yuasa Kawase, Miyako ^a   Nakatani, Kazuhiro ^a   Inagaki, Miwako ^a   Tsubakio Yamamoto, Kazumi ^a   Ohama, Tohru ^a   Matsuyama, Akifumi ^c   Nishida, Makoto ^b   Ishigami, Masato ^a   Komuro, Issei ^a   Yamashita, Shizuya ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Apolipoprotein B 48; CD36 deficiency; Ezetimibe; Long chain fatty acids; Postprandial hypertriglyceridemia

Indexed keywords

ACYL COENZYME A DESATURASE; APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; CHYLOMICRON REMNANT; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; EZETIMIBE; FATTY ACID BINDING PROTEIN 2; FATTY ACID TRANSPORTER 4; LIPOPROTEIN; LONG CHAIN FATTY ACID; MESSENGER RNA; OLIVE OIL; STEAROYL COENZYME A; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYMATIC ASSAY; FAT INTAKE; FATTY ACID METABOLISM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTRIGLYCERIDEMIA; INTESTINE CELL; INTESTINE LYMPH; INTESTINE MUCOSA; LIPID ABSORPTION; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PLASMA; POSTPRANDIAL HYPERTRIGLYCERIDEMIA; POSTPRANDIAL STATE; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRANSCRIPTION REGULATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77958538581     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.4929     Document Type: Article

References (31)

1. Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation and Treatment of High Blood cholesterol in Adults (Adult treatment panel III). Final Report. Circulation, 2002; 106: 3163-3223
2. Nordestgaard B, Benn M, Schnohr P, Tybjærg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308
3. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152
4. Huff MW: Dietary cholesterol, cholesterol absorption, postprandial lipemia and aterosclerosis. Can J Clin Pharmacol, 2003; 10 (Suppl A): 26A-32A
5. Zilversmit DB: Atherogenesis: A postprandial phenomenon. Circulation, 1979; 60: 473-485
6. Fujioka Y, Ishikawa Y: Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb, 2009; 16: 145-154
7. Tanaka A: Postprandial hypertriglyceridemia and atherosclerosis. J Atheroscler Thromb, 2004; 11: 322-329
8. Su X, Abumrad NA: Cellular fatty acid uptake: A pathway under construction. Trends Endocrinol Metab, 2009; 20: 72-77
9. Yamashita S, Hirano K, Kuwasako T, Janabi M, Toyama Y, Ishigami M, Sakai N: Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem, 2007; 299: 19-22
10. Goudriaan JR, den Boer MA, Rensen PC, Febbraio M, Kuipers F, Romijn JA, Havekes LM, Voshol PJ: CD36 deficiency in mice impairs lipoprotein lipase-mediated triglycerides clearance. J Lipid Res, 2005; 46: 2175-2181
11. Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y, Takada M, TsubakioYamamoto K, Tochino Y, Koseki M, Matsuura F, Nishida M, Kawamoto T, Ishigami M, Hori M, Shimomura I, Yamashita S: Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res, 2009; 50: 999-1011
12. Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL: The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab, 2008; 7: 508-519
13. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, MacCcubin D, Veltri E: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J, 2004; 148: 447-455
14. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol, 2006; 47: 1584-1587
15. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL: The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis, 2009; 202: 216-224
16. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC, Ohama T, Nishida M, Ishigami M, Yamashita S: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest, 2009; 39: 689-698
17. Moore KJ, J El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW: A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem, 2002; 277: 47373-47379
18. Okazaki M, Usui S, Fukui A, Kubota I, Tomoike H: Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem, 2006; 52: 2049-2053
19. Bollman, JL, Cain JC, Grindlay JH: Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med, 1949; 33: 1349-1352
20. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tezloff G, Iyer SPN, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004; 303: 1201-1204
21. Stahl A: A current review of fatty acid transport proteins (SLC27). Pflugers Arch, 2004; 447: 722-727
22. Milger K, Herrmann T, Becker C, Gotthardt D, Zickwolf J, Ehehait R, Watkins P, Stremmel W, Füllekrug J: Cellular uptake of fatty acids driven by the ER-localized acyl- CoA synthetase FATP4. J Cell Sci, 2006; 119: 4678-4688
23. Fisher RM, Gertow K: Fatty acid transport proteins and insulin resistance. Curr Opin Lipidol, 2005; 16: 173-178
24. Labonté ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP, Ioannou YA, Tso P, Hui DY, Howles PN: Reduced absorption of saturated fatty acids and resistance to diet induced obesity and diabetes by ezetimibetreated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol, 2008; 295: G776-G783
25. Yen CLE, Stone SJ, koliwad S, Harris C, Farese RV: DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res, 2008; 49: 2283-2301
26. Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM: Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J Biol Chem, 2007; 282: 2483-2493
27. Man WC, Miyazaki M, Chu K, Ntambi J: Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis. J Lipid Res, 2006; 47: 1928-1939
28. Hirano K, Young SG, Farese RV Jr, Ng J, Sande E, Warburton C, Powell-Braxton LM, Davidson NO: Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J Biol Chem, 1996; 271: 9887-9990
29. Maris C, Masse J, Chester A, Navaratnam N, Allain FHT: NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor. RNA, 2005; 11: 173-186
30. Chester A, Weinreb V, Carter CW, Navaratnam N: Optimization of apolipoprotein B mRNA editing by APO-BEC1 apoenzyme and the role of its auxiliary factor, ACF. RNA, 2004; 10: 1399-1411
31. Blanc V, Henderson JO, Newberry EP, Kennedy S, Luo J, Davidson NO: Targeted deletion of the murine apobec-1 complementation factor (acf) gene results in embryonic lethality. Mol Cell Biol, 2005; 25: 7260-7269